GILEAD SCIENCES, LDA secures contract for General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents - 2024/0900 - EMTRICITABINA RILPIVIRINA TENOFOVIR ALAFENAMIDA [200 25 25 MG; COMP]

Posted On: 2025-06-17

Portugal, June 17 -- Portugal based GILEAD SCIENCES, LDA has secured contract from Unidade Local de Saude Santa Maria, E.P.E. for General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents - 2024/0900 - EMTRICITABINA RILPIVIRINA TENOFOVIR ALAFENAMIDA [200 25 25 MG; COMP]. The value of the contract is worth 104931750 EUR.

Published by HT Digital Content Services with permission from Pivotal Sources....

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

GILEAD SCIENCES, LDA secures contract for General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents - 2024/0900 - EMTRICITABINA RILPIVIRINA TENOFOVIR ALAFENAMIDA [200 25 25 MG; COMP]